Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 9/20 | 0.86 |
| ▸ | KDR | P35968 | 5/20 | 0.71 |
| ▸ | FLT1 | P17948 | 3/20 | 0.71 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 3/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796059 | 0.93 | TEK (1.00) | TEKKDRFLT1BRAFMAP4K4 | |
| SCHEMBL4480247 | 0.89 | TEK (0.85) | TEKKDRFLT1BRAFMAP4K4 | |
| SCHEMBL4471994 | 0.89 | TEK (0.85) | TEKKDRFLT1BRAFKIT | |
| SCHEMBL4801489 | 0.87 | TEK (0.83) | TEKKDRFLT1BRAFLIMK1 | |
| SCHEMBL4467818 | 0.86 | TEK (0.83) | TEKKDRFLT1BRAFMAP4K4 | |
| SCHEMBL4484707 | 0.86 | TEK (0.83) | TEKKDRFLT1BRAFKIT | |
| SCHEMBL4796015 | 0.85 | TEK (0.86) | TEKKDRFLT1MAP4K4LIMK1 | |
| SCHEMBL4471484 | 0.84 | TEK (0.73) | TEKKDRFLT1BRAFMAP4K4 | |
| SCHEMBL4485440 | 0.84 | TEK (0.70) | TEKKDRFLT1MAP4K4LIMK1 | |
| SCHEMBL4476973 | 0.84 | TEK (0.73) | TEKKDRFLT1BRAFMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | claimed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | claimed |
| EP-1537112-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | Astrazeneca AB (SE) | 2005-06-08 | — | — | EP | claimed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | claimed |
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1537112-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | Astrazeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | TEK 2/4885KDR 3/4885FLT1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.